186 related articles for article (PubMed ID: 23868727)
1. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Stewart JE; Ma X; Megison M; Nabers H; Cance WG; Kurenova EV; Beierle EA
Mol Carcinog; 2015 Jan; 54(1):9-23. PubMed ID: 23868727
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Beierle EA; Ma X; Stewart JE; Megison M; Cance WG; Kurenova EV
Mol Carcinog; 2014 Mar; 53(3):230-42. PubMed ID: 23065847
[TBL] [Abstract][Full Text] [Related]
3. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
4. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Kurenova EV; Hunt DL; He D; Magis AT; Ostrov DA; Cance WG
J Med Chem; 2009 Aug; 52(15):4716-24. PubMed ID: 19610651
[TBL] [Abstract][Full Text] [Related]
5. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.
Gillory LA; Stewart JE; Megison ML; Waters AM; Beierle EA
J Surg Res; 2015 Jun; 196(2):339-49. PubMed ID: 25862488
[TBL] [Abstract][Full Text] [Related]
7. FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.
Megison ML; Gillory LA; Stewart JE; Nabers HC; Mrozcek-Musulman E; Beierle EA
Mol Cancer Res; 2014 Apr; 12(4):514-26. PubMed ID: 24464916
[TBL] [Abstract][Full Text] [Related]
8. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
Megison ML; Stewart JE; Nabers HC; Gillory LA; Beierle EA
Clin Exp Metastasis; 2013 Jun; 30(5):555-68. PubMed ID: 23208732
[TBL] [Abstract][Full Text] [Related]
9. FAK is a critical regulator of neuroblastoma liver metastasis.
Lee S; Qiao J; Paul P; O'Connor KL; Evers MB; Chung DH
Oncotarget; 2012 Dec; 3(12):1576-87. PubMed ID: 23211542
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
[TBL] [Abstract][Full Text] [Related]
11. Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Stafman LL; Williams AP; Marayati R; Aye JM; Markert HR; Garner EF; Quinn CH; Lallani SB; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Sci Rep; 2019 Sep; 9(1):13259. PubMed ID: 31519958
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
[TBL] [Abstract][Full Text] [Related]
13. Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.
Gogate PN; Kurenova EV; Ethirajan M; Liao J; Yemma M; Sen A; Pandey RK; Cance WG
Cancer Lett; 2014 Oct; 353(2):281-9. PubMed ID: 25067788
[TBL] [Abstract][Full Text] [Related]
14. Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.
Guessous F; Yang Y; Johnson E; Marcinkiewicz L; Smith M; Zhang Y; Kofman A; Schiff D; Christensen J; Abounader R
Mol Cancer Ther; 2012 Feb; 11(2):288-97. PubMed ID: 22188814
[TBL] [Abstract][Full Text] [Related]
15. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Chen H; Suo K; Cheng Y; Zheng B; Xu L
Gynecol Endocrinol; 2013 Jan; 29(1):20-4. PubMed ID: 22817694
[TBL] [Abstract][Full Text] [Related]
18. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Golubovskaya VM; Ho B; Zheng M; Magis A; Ostrov D; Morrison C; Cance WG
BMC Cancer; 2013 Jul; 13():342. PubMed ID: 23841915
[TBL] [Abstract][Full Text] [Related]
19. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.
Mehta RR; Yamada T; Taylor BN; Christov K; King ML; Majumdar D; Lekmine F; Tiruppathi C; Shilkaitis A; Bratescu L; Green A; Beattie CW; Das Gupta TK
Angiogenesis; 2011 Sep; 14(3):355-69. PubMed ID: 21667138
[TBL] [Abstract][Full Text] [Related]
20. Serine-Threonine Kinase Receptor Associate Protein (STRAP) confers an aggressive phenotype in neuroblastoma via regulation of Focal Adhesion Kinase (FAK).
Bownes LV; Marayati R; Quinn CH; Hutchins SC; Stewart JE; Anderson JC; Willey CD; Datta PK; Beierle EA
J Pediatr Surg; 2022 Jun; 57(6):1026-1032. PubMed ID: 35272839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
